Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Abeona Therapeutics (ABEO) EBIT: 2011-2025

Historic EBIT for Abeona Therapeutics (ABEO) over the last 14 years, with Sep 2025 value amounting to -$24.0 million.

  • Abeona Therapeutics' EBIT fell 56.52% to -$24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.2 million, marking a year-over-year decrease of 36.97%. This contributed to the annual value of -$64.2 million for FY2024, which is 36.23% down from last year.
  • As of Q3 2025, Abeona Therapeutics' EBIT stood at -$24.0 million, which was down 5.38% from -$22.8 million recorded in Q2 2025.
  • Abeona Therapeutics' EBIT's 5-year high stood at -$8.0 million during Q2 2022, with a 5-year trough of -$46.7 million in Q4 2021.
  • For the 3-year period, Abeona Therapeutics' EBIT averaged around -$16.2 million, with its median value being -$15.3 million (2024).
  • In the last 5 years, Abeona Therapeutics' EBIT slumped by 222.18% in 2021 and then soared by 72.27% in 2022.
  • Over the past 5 years, Abeona Therapeutics' EBIT (Quarterly) stood at -$46.7 million in 2021, then soared by 72.27% to -$12.9 million in 2022, then dropped by 2.11% to -$13.2 million in 2023, then fell by 26.22% to -$16.7 million in 2024, then plummeted by 56.52% to -$24.0 million in 2025.
  • Its EBIT was -$24.0 million in Q3 2025, compared to -$22.8 million in Q2 2025 and -$19.7 million in Q1 2025.